Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 3;7(4):a026187.
doi: 10.1101/cshperspect.a026187.

Inherited TP53 Mutations and the Li-Fraumeni Syndrome

Tanya Guha  1 , David Malkin  2
Affiliations
Review

Inherited TP53 Mutations and the Li-Fraumeni Syndrome

Tanya Guha et al. Cold Spring Harb Perspect Med. .

Abstract

Li-Fraumeni syndrome (LFS) is a complex hereditary cancer predisposition disorder associated with early-onset cancers in diverse tissues of origin. Germline TP53 mutations are identified in 75% of patients with classic LFS. The lifetime likelihood of a TP53 mutation carrier developing cancer approaches 75% in males and almost 100% in females. Several genetic modifiers have been implicated to account for the phenotypic variability within and across LFS families; however, efforts to develop predictive algorithms of age of onset and type of cancers in individual patients have not yet found clinical use. Although it is not possible to prevent cancers from forming in LFS patients, novel protocols have been developed for surveillance for early tumor detection, leading to improvements in survival. Comprehensive studies of the genome and epigenome in LFS families in the context of germline TP53 mutations is anticipated to shed light on this intriguing, yet devastating, disease and to transform the clinical management of patients.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Five core cancers associated with Li–Fraumeni syndrome (LFS).
See this image and copyright information in PMC

References

    1. Achatz MI, Zambetti GP. 2016. The inherited p53 mutation in the Brazilian population. Cold Spring Harb Perspect Med 10.1101/cshperspect.a026195. - DOI - PMC - PubMed
    1. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, et al. 1994. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li–Fraumeni families. Cancer Res 54: 1298–1304. - PubMed
    1. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591–602. - PubMed
    1. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, et al. 2006. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li–Fraumeni syndrome. J Med Genet 43: 531–533. - PMC - PubMed
    1. Brown BW, Costello TJ, Hwang SJ, Strong LC. 2005. Generation or birth cohort effect on cancer risk in Li–Fraumeni syndrome. Hum Genet 118: 489–498. - PubMed

Substances

LinkOut - more resources